Company
Advanz Pharma
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
11
9 still marketed
Novel approvals
8
Approvals since 2021
0
Originals and new uses
Phase 3 trials
6
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Uroxatral new use Priority reviewDec 15, 2010
- Orapred Odt approved Jun 1, 2006
- Uroxatral approved NovelJun 12, 2003
- Zonegran approved NovelMar 27, 2000
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (9)
Newest FDA action first.
- Panretin Alitretinoin · 1999
- Orapred Odt Prednisolone Sodium Phosphate · 2006
- Lanoxin Digoxin · 1997
- Plaquenil Hydroxychloroquine Sulfate · 1955
- Uroxatral Alfuzosin Hydrochloride · 2003
- Zonegran Zonisamide · 2000
- Parnate Tranylcypromine Sulfate · 1961
- Salagen Pilocarpine Hydrochloride · 1994
- Dyrenium Triamterene · 1964
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.